ANNUAL SURVIVAL RATES IN MPACT8 ANNUAL SURVIVAL RATES IN MPACT8

Overall survival prespecified analysis of the MPACT trial Overall survival prespecified analysis of the MPACT trial
Post-Hoc analysis of Long Terms Survivors Data from the MPACT study
aAnalysis Limitations: A post-hoc exploratory analysis should not be interpreted to determine a treatment difference between arms at these selected time points, because of potential selection bias, insufficient sample size, and a higher probability of making a false positive error.

  • bThe initial publication of the MPACT study reported an OS analysis in which 80% of patients had died. This data is from an updated analysis of OS from MPACT with an extended data cutoff (8 months longer) at the time the trial was closed. At that time, 90% of patients in the intent-to-treat (ITT) population had died.8
  • cStratified using Cox proportional hazard model.
  • dBased on a stratified log-rank test (stratified by geographic region, KPS, and presence of liver metastasis).

YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL